2021 dermal-filler sales will make a dent in the cash burn, but they won’t offset it entirely. RVNC’s guidance for 2021 cash operating expenses is $270-285M (#msg-162045598). I will be happy if 2021 dermal-filler sales reach $100M.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”